No Effect of Immunogenicity on Pharmacokinetics, Efficacy, and Safety of the Oligonucleotide Telomerase Inhibitor Imetelstat in Lower‐Risk Myelodysplastic Syndromes

Documenti analoghi

• Imetelstat, a novel, first‐in‐class telomerase inhibitor: Mechanism of action, clinical, and translational science
  di: Ashley L. Lennox, et al.
  Pubblicazione: (2024)
• Effect of E7777 Immunogenicity on Pharmacokinetics, Efficacy, and Safety in Adult Patients With Relapsed or Refractory Cutaneous T‐Cell Lymphoma
  di: Theingi M. Thway, et al.
  Pubblicazione: (2025)
• Safety, Pharmacokinetics, and Immunogenicity of Astegolimab, an Anti‐ST2 Monoclonal Antibody, in Randomized, Phase I Clinical Studies
  di: Wenhui Zhang, et al.
  Pubblicazione: (2025)
• Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Immunogenicity of ALXN1820 (Tarperprumig) in Healthy Adults: Results of a Phase I Study
  di: Avner Sandhu, et al.
  Pubblicazione: (2025)
• Pharmacokinetics and Safety of Pelacarsen, a GalNAc 3 ‐Conjugated Antisense Oligonucleotide Targeting Apo(a), in Participants With Mild Hepatic Impairment
  di: Jing‐He Yan, et al.
  Pubblicazione: (2025)